efimosfermin - Search News

News

GSK, liver disease and efimosfermin

GSK to acquire Boston’s liver disease candidate efimosfermin in deal worth up to $2bn

GSK will gain access to efimosfermin by acquiring Boston’s subsidiary BP Asset IX for $1.2bn upfront and up to $800m in success-based milestone payments. The drugmaker will also be responsible for success-based milestone payments as well as tiered royalties for efimosfermin owed to Novartis Pharma.

PMLive · 37m

Medical Dialogues · 1h

GSK to acquire liver disease drug Efimosfermin for up to USD 2 billion

· 21h · on MSN

GSK to buy liver disease drug for up to $2 billion

1don MSN

GSK to buy efimosfermin for up to $2 billion

British pharmaceutical giant GSK on Wednesday said it will buy efimosfermin, a phase III-ready potential specialty medicine ...

Pharmabiz7h

GSK to buy Boston Pharma’s efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of SLD

GSK to buy Boston Pharma’s efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of SLD: London, UK Thursday, May 15, 2025, ...

Medscape5d

Once-Monthly Efimosfermin Leads to Significant MASH Improvement in Phase 2 Trial

Once-monthly efimosfermin alfa prescribed for metabolic dysfunction–associated steatohepatitis with F2 and F3 fibrosis ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results